3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Spinocerebellar Degenerations
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Colorectal Neoplasms
1
Interventions
Cyclophosphamide
909
Carboplatin
787
pembrolizumab
744
Paclitaxel
742
Cisplatin
709
Bevacizumab
706
Gemcitabine
619
Docetaxel
579
Rituximab
548
Radiotherapy
541
Dexamethasone
511
Nivolumab
488
Doxorubicin
444
Fluorouracil
392
Capecitabine
376
Etoposide
358
Pemetrexed
337
Cytarabine
335
Oxaliplatin
333
Lenalidomide
328
Prednisone
326
fludarabine phosphate
316
Erlotinib Hydrochloride
314
Trastuzumab
300
Leucovorin
299
fludarabine
296
Vincristine
287
Filgrastim
284
Bortezomib
284
Cetuximab
276
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Has results
×
vicriviroc
×
Clear all
NCT03631407
2024-11-21
MK-7690-046
Merck Sharp & Dohme LLC
Phase 2
Completed
41 enrolled
20 charts